RxDoctor Payments Data

Matthew Gilbert, NP

Nurse Practitioner · Virginia Beach, VANPI 1114442910

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (40.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 69.5% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $5,031, 3.0 times the $1,662 reported in 2021. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,556in general payments, 2019–2025

Across 134 payments — averaging $71.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$7K
  • Teleflex LLC$1K
  • Coloplast$517
  • Clarus Therapeutics Inc.$212
  • Bayer$158
  • Sumitomo Pharma America, Inc.$148
  • plus $494 from 9 others

What the payments were for

  • Speaking & faculty fees$3,84840%
  • Travel & lodging$2,36025%
  • Food & beverage$3,34835%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,556 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$191,208
Medicare patients
948
Services billed
4,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron83$80,633
GemtesaVibegron15$22,081
Testosterone70$17,840
Tadalafil20$11,070
Testosterone Cypionate190$10,575
Tamsulosin Hcl478$6,937
Finasteride226$2,964
Solifenacin Succinate38$1,895
Silodosin24$1,704
Alfuzosin Hcl ErAlfuzosin Hcl44$732
Oxybutynin Chloride ErOxybutynin Chloride29$698
Dutasteride22$692
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst29$389
CiclopiroxCiclopirox Olamine14$173
Doxycycline Hyclate15$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$148$22,08115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →